Everyone Deserves To Know The Right Treatment
How Ataraxis Breast Works
Ataraxis tests consider information about you and the tumor to assess the aggressiveness of breast cancer and provide accurate, individualized recurrence risk assessment.
.png)
.png)
Ataraxis Breast was Validated in Patients Like You
Ataraxis Breast tests have been developed and validated using recent data of thousands of real patients from around the world. Our clinical studies show that Ataraxis Breast RISK, our test predicting risk of breast cancer recurrence, can distinguish between low and high risk in all patients with early-stage breast cancer, no matter their age, race, molecular subtype, or histology.
Choose the characteristics that best describe you. We’ll show evidence from our clinical validation study with patients like you.
Read more about Ataraxis’s clinical evidence
Read MoreFrequently Asked Questions
Ataraxis Breast RISK is available for women with stage I–III invasive breast cancer, across all subtypes and independent of nodal or hormone receptor status.
The Ataraxis Breast RISK test has been extensively validated in large and diverse patient populations. The algorithm was developed and evaluated using data from more than 10,000 patients. It has been clinically validated in diverse patient populations, including challenging and more rare subtypes of breast cancer and patient groups, demonstrating consistent performance.
Ataraxis Breast RISK is a prognostic test, which predicts overall risk of breast cancer recurrence. It does not make any specific treatment recommendations, and it estimates recurrence risk assuming standard of care treatment.
Most results are shared with physicians within one business day once the lab receives the pathology slide.